A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients With Relapsed or Refractory Follicular Lymphoma.

Trial Profile

A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients With Relapsed or Refractory Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Galiximab (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 25 Dec 2009 Planned end date changed from 1 Dec 2003 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Planned number of patients (42) added as reported by ClinicalTrials.gov.
    • 18 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top